Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,446 total articles
South Plains Financial, Inc., the parent company of City Bank, announced that it will release its second quarter 2026 financial results before market open on July 17, 2026, with a conference call and webcast scheduled for 8:30 a.m. ET the same day to discuss the results. The company is a Texas-based bank holding company serving various Texas market…
BriaCell Therapeutics Corp. has engaged Charles River Associates and Kaleio to evaluate commercial strategy, brand planning, and market access potential for Bria-IMT, currently in a pivotal Phase 3 trial for metastatic breast cancer. These steps show proactive preparation for potential future commercialization, subject to regulatory approval and su…
Streamex Corp., a technology and infrastructure company specializing in tokenization of commodity real-world assets, announced a board-authorized share repurchase program to buy back up to 10 million shares at prices up to $2.00 per share within the next year. The program reflects the company's confidence in its intrinsic value and long-term growth…
Dyadic International reported significant progress in validating its proprietary C1 protein production platform through multiple global health collaborations, including partnerships supported by the Gates Foundation, CEPI, and Scripps Research. The C1 platform demonstrated faster, high-yield, and cost-efficient production of biologics such as monoc…
Alterity Therapeutics received official FDA End-of-Phase 2 meeting minutes confirming agreement on the Phase 3 clinical trial design for ATH434 in Multiple System Atrophy (MSA). The FDA agreed that a single pivotal Phase 3 trial supported by confirmatory evidence from prior Phase 2 trials could underpin potential drug approval, with trial initiatio…
Gilat Satellite Networks' subsidiary, Gilat DataPath, received $11 million in orders from the U.S. Department of War to supply custom SATCOM terminals and field services, highlighting the company's expanding footprint in mission-critical defense communication solutions. Deliveries are expected over the coming 12 months, underlining Gilat Defense's …
Tvardi Therapeutics announced positive Phase 1 trial results for its novel oral STAT3 inhibitor, TTI-109, demonstrating rapid prodrug conversion to TTI-101, improved tolerability compared to the parent compound, and significant reductions in STAT3-driven immune cell populations. The company plans to advance TTI-109 into dermatologic and gastrointes…
Agios Pharmaceuticals announced that the FDA has accepted its supplemental New Drug Application for mitapivat, an oral pyruvate kinase activator aimed at treating sickle cell disease, granting it Priority Review status with a PDUFA goal date of November 1, 2026. If approved, mitapivat would be the first oral PK activator for this indication, built …
onsemi announced agreements to divest manufacturing facilities in Tarlac, Philippines and Mountain Top, Pennsylvania as part of its Fab Right strategy aimed at optimizing manufacturing footprint and improving cost efficiency. The divestitures are expected to generate annual cost savings of approximately $35 million by 2028 and ensure continuity thr…
Healthcare Realty Trust Incorporated, a leading owner and operator of medical outpatient buildings in the U.S., will release its second quarter 2026 earnings on July 30, 2026, followed by a conference call on July 31 to discuss results, company activities, and industry trends.
Plug Power announced that the Hunter Valley Hydrogen Hub project in Australia, developed by Orica, has reached final investment decision, advancing the deployment of Plug’s 50MW GenEco PEM electrolyzers. The project, the largest green hydrogen initiative in Australia to reach FID, will produce approximately 4,700 tonnes of renewable hydrogen annual…
Axsome Therapeutics has initiated dosing in the FOCUS-2 Phase 3 clinical trial to evaluate solriamfetol as a treatment for children aged 6 to under 12 with ADHD, complementing an ongoing adolescent trial (FOCUS-3). The double-blind, placebo-controlled study will assess efficacy and safety in approximately 468 patients. This program targets a signif…
Annovis Bio has fully enrolled 850 patients in its pivotal Phase 3 trial of buntanetap for early Alzheimer's disease, exceeding initial projections. The trial's dual primary endpoints will assess symptomatic and disease-modifying effects, with data readouts expected in Q1 2027 and Q1 2028 respectively. The company plans two New Drug Application sub…
Wrap Technologies, Inc. announced the launch of WrapShield, an autonomous defense and public safety platform that integrates advanced thermal polarimetric sensing technology from Frenel Imaging Ltd. The platform connects detection, AI-assisted decision-making, and response across public safety, defense, and critical infrastructure sectors. Starting…
Avalo Therapeutics announced its participation in the Leerink Partners Therapeutics Forum with management hosting investor meetings to discuss its clinical stage developments targeting the IL-1β pathway for immune-mediated inflammatory diseases. Their lead asset, abdakibart, showed positive Phase 2 topline data in hidradenitis suppurativa. The comp…
Aeluma, Inc., a US-based semiconductor company specializing in scalable photonic and electronic technologies, announced that its CEO Jonathan Klamkin will chair the Industry Program at the Optica Advanced Photonics Congress. Additionally, the company will present a technical paper on its scalable quantum dot laser technology targeted for AI datacom…
Kailera Therapeutics announced positive topline results from two Phase 3 trials conducted by Hengrui Pharma on their oral GLP-1 receptor agonist HRS-7535 (KAI-7535) in China. The obesity trial showed significant mean weight loss up to 11.1% at week 50, and the type 2 diabetes trial demonstrated HbA1c reductions outperforming the comparator dapaglif…
OKYO Pharma Limited, a Nasdaq-listed clinical-stage biopharmaceutical company, announced its participation in a virtual fireside chat at the Piper Sandler 2026 Virtual Ophthalmology Symposium. Company executives will discuss progress on their flagship drug urcosimod for neuropathic corneal pain (NCP), including successful phase 2 results and plans …
Teva Pharmaceutical Industries announced it will advance its investigational anti-interleukin-15 monoclonal antibody TEV-408 into a Phase 2b clinical trial for vitiligo following encouraging Phase 1b study outcomes. The Phase 1b data showed that TEV-408 was well tolerated and led to improvement in skin pigmentation among patients with active or sta…
Aqua Metals, Inc. advances to final site diligence and negotiations for Headwaters ARC, a large-scale commercial battery recycling and critical minerals recovery facility in the Midwest, aiming to serve expanding lithium iron phosphate (LFP) battery manufacturing hubs. The phased project will start with battery preprocessing and black mass producti…
Nuvini Group Limited announced the full repayment of its R$61 million non-convertible debenture facility, marking the culmination of a multi-year deleveraging effort. This repayment removes associated covenants and liens, enhancing the company's capital structure and enabling greater flexibility to pursue its acquisition strategy across Latin Ameri…
Aclarion, Inc., a healthcare technology company specializing in biomarker-driven diagnostics for chronic low back pain, announced that Texas Spine Care Center has joined its CLARITY clinical trial. The CLARITY trial is a multi-center, randomized study evaluating Aclarion's Nociscan platform designed to identify painful discs in patients with chroni…
Kymera Therapeutics announced the appointment of Elizabeth Laws, Ph.D., as Senior Vice President and Global Program Team Leader for KT-621, an innovative oral STAT6 degrader targeting immunological diseases. Dr. Laws brings extensive experience from Sanofi, including leadership in immunology drug development and commercialization. KT-621 is advanci…
Aquestive Therapeutics announced its participation in the Leerink Partners Therapeutics Forum focusing on immunology, inflammation, and metabolism, where management will hold one-on-one investor meetings. The company is advancing its proprietary medicines using innovative oral film delivery technology and developing new therapies such as Anaphylm™ …
AC Immune SA announces three presentations at the Alzheimer's Association International Conference 2026 showcasing its cutting-edge Morphomer®-based therapies and diagnostics for neurodegenerative diseases, including new imaging agents and novel inhibitors currently in clinical and preclinical development.
